Details of the Drug Reposition

General Information of This Drug (ID: DMTV42K)

Drug Name
G1   DMTV42K
Synonyms
CHEMBL569766; 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethanone; 1-(4-(6-Bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone; SR-01000506928; AC1NT1SF; GTPL1014; SCHEMBL12700948; cid_5322399; cid_3136849; MolPort-003-004-976; ML051; HMS3650I22; ZINC4172149; BDBM50303803; STK330808; AKOS015969580; HY-107216; CS-0027669; UNM000011063001; UNM000000675701; SR-01000506928-1; SR-01000506928-3; 925419-53-0
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [1]
Lymphoma DISN6V4S 2A80-2A86 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04130516) Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and in Combination With Pembrolizumab. U.S. National Institutes of Health.